Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- SELLAS Life Sciences Presents Preclinical Data Demonstrating SLS009 Activity in Pancreatic Cancer Models at the 2026 AACR Conference on Pancreatic CancerSELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced preclinical data from studies evaluating SLS009 (tambiciclib), its highly selective cyclin-dependent kinases 9 (CDK9) inhibitor, in patient-derived organoid models of pancreatic ductal adenocarcinoma (PDAC). The data are being presented at the American Association for Cancer Research (AACR) Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development, being held September 25–28, 2026, in San Diego. The timing of this announcement reflects AACR’s embargo policy, under which the data presented at the conference were restricted from publication until 1:00 p.m. ET today.
- Knight TherapeuticsKnight Therapeutics Inc. places No. 345 on The Globe and Mail’s eighth annual ranking of Canada's Top Growing CompaniesKnight Therapeutics Inc. (TSX:GUD) (“Knight” or “the Company”) is pleased to announce it has ranked No. 345 on the 2026 Report on Business magazine’s ranking of Canada’s Top Growing Companies.
- NanexaNanexa and Novo enter into EUR 1.165 billion global license and collaboration agreement for long-acting injectablesThe agreement grants Novo a global exclusive license to Nanexa's proprietary PharmaShell® atomic layer deposition (ALD) drug delivery technology platform for certain therapeutic peptide drugs in indications including obesity, type 2 diabetes and other cardiometabolic diseases. The...
- Nutshell Therapeutics (Shanghai) Co., Ltd.Second NRF2 Degrader Enters Clinical Development: Nutshell Therapeutics' NTS231 Received FDA IND ClearanceNutshell Therapeutics (Shanghai) Co., Ltd. ("Nutshell Therapeutics"), an innovative biotech company focused on AI-driven allosteric drug discovery, announced FDA IND clearance for NTS231, a covalent allosteric molecular glue degrader of NRF2, to...
- Avacta Group plc: The FOCUS-01 Clinical Trial Design and Preclinical Data Further Demonstrate the Potential of AVA6103 at AACR Conference on Pancreatic CancerAvacta Therapeutics (AIM: AVCT, the "Company", "Avacta"), a life sciences company developing innovative, targeted oncology drugs, today announces the presentation of the FOCUS-01 trial design and preclinical data highlighting the potential of AVA6103 (FAP-Exd) in pancreatic ductal adenocarcinoma (PDAC). FOCUS-01 is the Phase 1 trial of AVA6103, the Company's first Next-Generation pre|CISION® peptide-drug conjugate (PDC) and is being presented at the American Association for Cancer Research ("AACR") Conference on Pancreatic Cancer in San Diego, California, held between 25-28 September 2026.
- CROSSJECT structure sa gouvernance pour la phase de déploiement industriel et commercialDIJON, FRANCE, 25 septembre 2026 – 07h30 (CEST) – CROSSJECT (ISIN : FR0011716265 ; Euronext Growth : ALCJ), la Specialty Pharma qui développe des solutions innovantes dédiées aux situations d’urgence, reposant sur sa technologie unique d’auto-injecteur sans aiguille ZENEO®, annonce que son Conseil de Surveillance, réuni le 24 septembre 2026, a nommé à l’unanimité Olivier LACOMBE, Didier MORIN et Lionel SELTZ membres du Directoire, leur nomination prend effet immédiatement et leur mandat expirera le 17 février 2029.
- The Independent Commission Against Corruption of Hong Kong, ChinaICAC and UNODC's pioneering international anti-graft training brings together law enforcers worldwide to combat illicit enrichmentThe ICAC, the Hong Kong International Academy Against Corruption, the United Nations Office on Drugs and Crime (UNODC) and the Global Operational Network of Anti-Corruption Law Enforcement Authorities (GlobE Network) jointly organised the...
- The Rosen Law Firm PAROSEN, A RANKED AND LEADING LAW FIRM, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCYWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between December 29, 2025 and June 29, 2026, both dates inclusive (the "Class Period"), of the important November 2, 2026 lead plaintiff deadline.SO WHAT: If you purchased Unicycive securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs...
- ADARx Pharmaceuticals Announces Pricing of Upsized $446.3 Million Initial Public OfferingADARx Pharmaceuticals Announces Pricing of Upsized $446.3 Million Initial Public Offering
- REGENXBIO Inc.REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific MeetingMajority of Dose Level 3 participants with NPDR demonstrated a > 2-step DRSS improvement at 3 years post-one-time, in-office sura-vec gene therapy treatment, with no vision-threatening events and no additional treatment for diabetic retinopathy No IOI observed with short-course...
- Fuse Oncology, Inc.Fuse Oncology Extends FuseRx Beyond the Physician to the Full Radiation Oncology Care TeamBeyond treatment intent, the complete clinical workflow will include tools for the physician, physicist, dosimetrist, therapist and nurse. It builds on collaboration with the University of Michigan and Cone Health, part of Risant Health. BOONE, N.C., Sept. 24, 2026 -- Fuse...
- National Foundation for Infectious DiseasesNew Survey: Most US Adults Support Vaccines, but Many Remain Unclear About Respiratory Vaccine RecommendationsSupport for vaccines is high — vaccination isn't. More than half of US adults did not try to get a flu, COVID-19, RSV, or pneumococcal vaccine in the past year, and many remain unsure which ones are recommended for them NFID launches National Respiratory Communications Initiative to help...